What is the recommended dose of artesunate (oral tablets) for the treatment of uncomplicated malaria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Artesunate Oral Tablet Dosing for Uncomplicated Malaria

For uncomplicated P. falciparum malaria in adults, oral artesunate is dosed at 4 mg/kg/day for 3 days, and must be followed by a full course of a partner drug (typically mefloquine 25 mg/kg or doxycycline 100 mg twice daily for 7 days) to prevent recrudescence. 1, 2

Dosing Regimens by Weight

Artesunate Monotherapy (Initial Phase)

  • Standard dose: 4 mg/kg body weight once daily for 3 days 3, 2, 4
  • Alternative regimen: 4 mg/kg on day 1, then 2 mg/kg daily on days 2-5 (5-day course) 5

Combination Therapy (Preferred)

Artesunate + Mefloquine (Most Effective for Resistant Areas)

  • Artesunate: 4 mg/kg/day for 3 days
  • Mefloquine: Either 8 mg/kg/day for 3 days (co-administered with artesunate) OR 15 mg/kg on day 1 plus 10 mg/kg on day 2 3, 2, 4
  • Total mefloquine dose: 25 mg/kg over the treatment course 4

Artesunate + Doxycycline

  • Artesunate: 4 mg/kg/day for 3 days
  • Doxycycline: 100 mg twice daily for 7 days (in patients ≥8 years old) 2

Critical Clinical Considerations

Why Combination Therapy is Essential

Artesunate monotherapy, even for 5 days, yields only a 90% cure rate and should not be used alone. 5 The addition of a partner drug is mandatory to achieve cure rates exceeding 98% and prevent the development of artemisinin resistance. 4

Severe vs. Uncomplicated Malaria Distinction

  • Oral artesunate is only for uncomplicated malaria 1, 2
  • For severe malaria, intravenous artesunate at 2.4 mg/kg is required at 0,12, and 24 hours, then daily until parasitemia <1% and oral intake is tolerated 6, 1
  • Patients with hyperparasitemia (>4% parasitemia) can be treated with oral artesunate if they have no vital organ dysfunction 7

Monitoring Requirements

  • Parasitemia should be checked on day 3 (expect 75% reduction) and day 7 (expect negative result) 6
  • Post-artesunate delayed hemolysis (PADH) monitoring is essential: check hemoglobin, haptoglobin, and LDH on days 7,14,21, and 28, as PADH occurs in up to 37.4% of patients 6, 8

Geographic Resistance Considerations

For patients from the Greater Mekong sub-region (Southeast Asia), artesunate-based combinations may have reduced efficacy due to artemisinin resistance. 6, 8 In these cases, consider alternative regimens such as atovaquone-proguanil. 6, 1

Administration Details

  • Oral artesunate can be taken with or without food 2, 5
  • When combined with mefloquine, giving mefloquine on day 2 (rather than day 1) significantly reduces vomiting (RR 0.40) 4
  • Fever clearance typically occurs within 19-32 hours, and parasite clearance within 36-43 hours 3, 7

Common Pitfalls to Avoid

  • Never use artesunate monotherapy without a partner drug - this promotes resistance and has unacceptably high failure rates 4, 5
  • Do not confuse oral dosing (4 mg/kg/day) with IV dosing (2.4 mg/kg) - these are different regimens for different disease severity 6, 2
  • Do not skip PADH monitoring - hemolysis can occur weeks after treatment and may be severe 6, 8

References

Guideline

Malaria Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Management of malaria in Thailand.

The Korean journal of parasitology, 2002

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria.

The American journal of tropical medicine and hygiene, 1995

Guideline

Contraindications and Precautions for Artesunate Use

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.